Low-cost scoring system informs HBV treatment eligibility in resource-limited countries

SAN DIEGO — A new, low-cost scoring system called TREAT-B accurately determined treatment eligibility for patients with hepatitis B virus, particularly where DNA assays are unavailable, according to research.“Major international guidelines have recommended the criteria for initiating treatment in patients with chronic hepatitis B infection. However, the hepatitis B DNA assay is not widely accessible and affordable, particularly in low- and middle-income countries. A simple score to indicate hepatitis B treatment eligibility is urgently needed to overcome the barriers for treatmentRead More

Categories: News

Related Articles

No difference in HCC risk between tenofovir, entecavir for chronic HBV infection

There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking tenofovir vs. entecavir to treat chronic hepatitis B virus infection,…

‘One size does not fit all’: Cirrhosis care access, mortality vary widely worldwide

LONDON — Cirrhosis severity, infections and mortality outcomes were worse for patients in low to middle-income countries, due in part to poor access to liver…

Earlier CRC screening with colonoscopy, FIT cost-effective ‘irrespective of BMI’

Regardless of patient sex or BMI, initiating colorectal cancer screening with colonoscopy at age 45 years or with fecal immunochemical testing at age 40 years…

September 1, 2022

Baseline MRI, scoring system predict Crohn’s outcomes

SAN DIEGO — Baseline magnetic resonance index of activity score independently predicted the longer-term need for surgery, rescue corticosteroids or hospitalizations among patients with Crohn’s…

Survey results suggest Black patients face greater barriers to IBD treatment

SAN DIEGO — Black patients with inflammatory bowel disease were more likely to use older therapies and face continued barriers to effective care, according to…